Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) fell 2.4% during mid-day trading on Monday . The company traded as low as $1.23 and last traded at $1.23. 61,251 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 328,917 shares. The stock had previously closed at $1.26.
Climb Bio Price Performance
The company has a market capitalization of $85.69 million, a PE ratio of -0.60 and a beta of -0.10. The business's 50-day moving average is $1.31.
Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its earnings results on Tuesday, March 25th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. As a group, sell-side analysts forecast that Climb Bio, Inc. will post -1.57 earnings per share for the current fiscal year.
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
See Also
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
